The characterization of the molecular mechanisms of misfolding and aggregation of target proteins — the hallmark of all neurodegenerative diseases (ND) — present researchers with unique challenges. On top of that, there are limitations in the bioanalytical methods currently used to study ND. This infographic presents 4 challenges and how NanoTemper bioanalytical tools overcome each one.
Have a question about Dianthus?
Contact SpecialistSee more related content
2:55Dianthus removes the complexity of binding interaction measurements for drug discovery screening. Find hits for any target type in any buffer or bioliquid, measure the tightest interactions down to pi
The NanoTemper Story – Chapter 5: The Dianthus
Almost as soon as the Monolith launched, the handful of people that made up NanoTemper in those early days huddled around, brainstorming how to translate the technology into a well-based assay....
17:10There are a number of interesting drug targets that have a reputation of being especially difficult to study in biochemical or biophysical assays. Join us to learn how Dianthus can help you address t
17:07A big hurdle in small molecule drug discovery screening is confidently identifying positive hits in a timely manner. Screening fragment libraries is challenging with current methodologies that are eit
3 big takeaways from SLAS on the future of automation and screening
5,200 researchers, representing all of life sciences, gathered in San Diego in late January to discuss the latest in automation and screening solutions. Improvements in automation and screening...
16:04Neurodegenerative diseases like Alzheimer’s or Parkinson’s Disease affect millions of people worldwide. Although current treatments may help relieve some of the physical or mental symptoms, there is s
When aptamers are the better choice over mAbs
Monoclonal antibodies (mAbs) have become the molecule of choice when highly specific molecular recognition is needed for a variety of applications including disease diagnosis and therapy....
6 ingredients for a successful fragment library
Fragment-based drug discovery (FBDD) has become a major strategy to derive novel lead candidates in drug discovery. The principle of FBDD is to start with very small molecular fragments which may...
PROTACs: the game-changing technology that promises to tackle “undruggable” proteins
Almost all pharmaceutical drugs today act by binding to disease-causing proteins and inhibiting their activity. Unfortunately, there are still many target proteins — as much as 85% of the human...
5 things you must do while in Liverpool for ELRIG Drug Discovery
Here’s how to make your trip unforgettable. 1. Immerse yourself in Liverpool’s historic heart at the Royal Albert Dock This is the place to be for many iconic Liverpool attractions. Discover...
5 things you must do in Barcelona while at SLAS Europe (according to a local)
Here’s how to make your trip memorable. 1. Be awe-inspired at La Sagrada Familia There’s nothing like it anywhere in the world. Architecture, nature and spirituality come together to create...
Answering the demands for a new screening tool for drug discovery with Dianthus
There’s a gap that exists in screening tools for drug discovery — the need for fast, easy to use and flexible devices isn’t being satisfied. Enter Dianthus, introduced to come to the rescue. At...
Great things start small and so does the discovery of drug candidates
The famous painter Vincent Van Gogh once said, “Great things are done by a series of small things brought together.” This is exactly how drugs are developed by means of fragment-based screening —...
NanoTemper Technologies Brings Speed to Drug Discovery Screening, Launches Dianthus System
PRESS RELEASE SOUTH SAN FRANCISCO, Calif. NanoTemper Technologies, maker of life science tools for protein characterization, launches its newest system, Dianthus, at the Society for Laboratory...